KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Restructuring Costs (2016 - 2026)

Eli Lilly filings provide 18 years of Restructuring Costs readings, the most recent being $279.0 million for Q1 2026.

  • On a quarterly basis, Restructuring Costs rose 697.14% to $279.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $728.0 million, a 18.75% decrease, with the full-year FY2025 number at $484.0 million, down 43.79% from a year prior.
  • Restructuring Costs hit $279.0 million in Q1 2026 for Eli Lilly, up from $84.1 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $435.0 million in Q2 2024 to a low of $35.0 million in Q1 2025.
  • Median Restructuring Costs over the past 5 years was $145.3 million (2022), compared with a mean of $193.7 million.
  • Biggest five-year swings in Restructuring Costs: crashed 75.58% in 2025 and later soared 697.14% in 2026.
  • Eli Lilly's Restructuring Costs stood at $38.1 million in 2022, then soared by 78.48% to $68.0 million in 2023, then soared by 406.47% to $344.4 million in 2024, then crashed by 75.58% to $84.1 million in 2025, then soared by 231.75% to $279.0 million in 2026.
  • The last three reported values for Restructuring Costs were $279.0 million (Q1 2026), $84.1 million (Q4 2025), and $364.9 million (Q3 2025) per Business Quant data.